Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer

Urology

Volumn 60, Issue 4 SUPPL., 2002, Pages 47-52

  Veltri, Robert W ^c   Miller, M Craig ^b   O'dowd, Gerard J ^b   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UroCor Incorporated   (United States)

^c Department of Urology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BENIGN TUMOR; BLOOD ANALYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR DIFFERENTIATION; UNITED STATES;

AGE FACTORS; AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0036792052     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01695-3     Document Type: Article

References (20)

1. O'Dowd G.J., Veltri R.W., Orozco R., et al. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol. 158:1997;687-698.
2. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen a decade of discovery: what we have learned and where we are going . J Urol. 162:1999;293-306.
3. Nadler R.B., Humphrey P.A., Smith D.S., et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 154:1995;407-413.
4. Lechevallier E., Echazarian C., Ortega J.-C., et al. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. Urology. 54:1999;857-861.
5. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men establishment of age-specific reference ranges . JAMA. 270:1993;860-864.
6. Partin A.W., Criley S.R., Subong E.N.P., et al. Standard versus age-specific antigen reference ranges among men with clinically localized prostate cancer a pathological analysis . J Urol. 155:1996;1336-1339.
7. Reissigl A., Pointner J., Horninger W., et al. Comparison of different prostate-specific antigen cutpoint for early detection of prostate cancer results of a large screening study . Urology. 46:1995;662-665.
8. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer receiver operating characteristic curves . J Urol. 152:1994;2037-2042.
9. Morgan T.O., Jacobson S.J., McCarthy W.F., et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 335:1996;304-310.
10. Catalona W.J., Ritchie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6630 men . J Urol. 151:1994;1283-1290.
11. Miller M.C., O'Dowd G.J., Partin A.W., et al. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer impact of changing demographics . Urology. 57:2001;1105-1111.
12. Allard W.J., Zhou Z., Yeung K.K. Novel measurement of complex prostate-specific antigen in serum. Clin Chem. 44:1998;1216-1223.
13. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
14. Veltri R.W., Miller M.C. Free/total PSA ratios improve differentiation of benign and malignant disease of the prostate critical analysis of two different test populations . Urology. 53:1999;736-745.
15. Stamey T.A., Yemoto C.E. Examination of the three molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy relationship to transition zone volume . J Urol. 163:2000;119-126.
16. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
17. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 163:2000;1476-1480.
18. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen the establishment of appropriate reference ranges for their concentrations and ratios . J Urol. 154:1995;1090-1095.
19. O'Dowd G.J., Miller M.C., Orozco R., et al. Analysis of repeat biopsy results within one year following a non-cancer diagnosis. Urology. 55:2000;553-559.
20. Presti J.C. Jr, Chang J.J., Bhargava V., et al. The optimal systematic biopsy scheme should include 8 rather than 6 biopsies results of a prospective clinical trial . J Urol. 167:2000;163-167.